
Oncotelic Therapeutics Reports Positive Safety Review for Phase 1b Sapu003 Trial
Oncotelic Therapeutics announced that an independent Safety Review Committee found no dose-limiting toxicities in the first patient cohort of its Sapu003 Phase 1b trial, clearing the way for dose escalation and European expansion.
Read full story























